178 related articles for article (PubMed ID: 23828279)
41. Pemetrexed for primary central nervous system lymphoma in the elderly.
Han S; Wang M; Liu B; Yu J
Clin Transl Oncol; 2016 Feb; 18(2):138-43. PubMed ID: 26169215
[TBL] [Abstract][Full Text] [Related]
42. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.
Gridelli C; de Marinis F; Thomas M; Prabhash K; El Kouri C; Blackhall F; Bustin F; Pujol JL; John WJ; San Antonio B; Zimmermann A; Chouaki N; Visseren-Grul C; Paz-Ares LG
J Thorac Oncol; 2014 Jul; 9(7):991-997. PubMed ID: 24926544
[TBL] [Abstract][Full Text] [Related]
43. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
44. A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.
Cohn AL; Myers JW; Mamus S; Deur C; Nicol S; Hood K; Khan MM; Ilegbodu D; Asmar L
Invest New Drugs; 2008 Aug; 26(4):381-6. PubMed ID: 18305899
[TBL] [Abstract][Full Text] [Related]
45. Pemetrexed: single-agent and combination phase I study overview.
Boyer MJ; Rivory LP; Clarke SJ
Semin Oncol; 2002 Dec; 29(6 Suppl 18):18-23. PubMed ID: 12571806
[TBL] [Abstract][Full Text] [Related]
46. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
[TBL] [Abstract][Full Text] [Related]
48. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
49. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
Cullen MH; Zatloukal P; Sörenson S; Novello S; Fischer JR; Joy AA; Zereu M; Peterson P; Visseren-Grul CM; Iscoe N
Ann Oncol; 2008 May; 19(5):939-45. PubMed ID: 18283036
[TBL] [Abstract][Full Text] [Related]
50. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
51. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.
Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G
Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262
[TBL] [Abstract][Full Text] [Related]
52. Post-treatment T1 shortening in primary CNS lymphoma.
Karimi S; Hatzoglou V; Punia V; Partovi S; Abrey LE; Deangelis LM
J Neurooncol; 2013 Jan; 111(1):25-31. PubMed ID: 23073601
[TBL] [Abstract][Full Text] [Related]
53. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.
Weiss GJ; Zeng C; Kelly K; Tran ZV; Bunn PA
Clin Lung Cancer; 2007 Mar; 8(5):335-8. PubMed ID: 17562234
[TBL] [Abstract][Full Text] [Related]
54. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
[TBL] [Abstract][Full Text] [Related]
55. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
56. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Russo F; Bearz A; Pampaloni G;
BMC Cancer; 2008 Jul; 8():216. PubMed ID: 18667090
[TBL] [Abstract][Full Text] [Related]
57. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
58. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
59. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
Vergote I; Calvert H; Kania M; Kaiser C; Zimmermann AH; Sehouli J
Eur J Cancer; 2009 May; 45(8):1415-23. PubMed ID: 19168349
[TBL] [Abstract][Full Text] [Related]
60. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
